Market Overview:
The global elephantiasis drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of elephantiasis, rising awareness about the disease, and technological advancements in the field of diagnostics and treatment. Based on type, the global elephantiasis drug market is segmented into EDE-1206, flubendazole, IIC-942A001, S-0112091 and others. Flubendazole is expected to account for a major share of the global elephantiasis drug market owing to its high efficacy and safety profile. Based on application, the global elephantiasis drug market is segmented into clinic, hospital and others. Clinic accounted for a major share of the overall application segment in 2017 owing to early diagnosis and treatment options available through clinics.
Product Definition:
The drug is used to treat elephantiasis, a condition caused by a parasitic infection that leads to enlargement of the limbs and other body parts.
EDE-1206:
S.I.
Flubendazole:
Flubendazole is an anti-parasitic drug and used for the treatment of Elephantiasis. It works by killing the parasites in the body. Flubendazole is also known as Lubendra or Lubenol, it's a white crystalline compound that has excellent solubility in water and is very soluble in alcohol. The chemical structure of flubendazole closely resembles that of a hormone called luteinizing hormone releasing factor (LHRF).
Application Insights:
Based on the application, the market is segmented into hospital, clinic and others. The hospital segment dominated the overall industry in terms of revenue in 2017. Hospital-based settings are more convenient for patients as they do not have to travel to a different location for treatment like clinics and other medical facilities do. However, this also leads to higher cost associated with it which is one of the factors that limit its penetration compared to other settings.
The clinic segment held a significant share of over 30% in 2017 owing to increasing awareness about elephantiasis among people across various regions coupled with rising number of diagnosed cases globally each year since 2014 (excluding 2016). As per WHO estimates published on January 2018, around 20 million people are living with chronic disease caused by filaria infection worldwide while another 80 million individuals are carriers or have been infected previously without developing symptoms due these infections being milder than primary ones or having them at all.
Regional Analysis:
Asia Pacific dominated the global elephantiasis drug market in 2017 with a revenue share of over 60%. The region is expected to maintain its position throughout the forecast period owing to increasing incidence of this disease coupled with growing awareness about early diagnosis. Moreover, availability of generic EDE-1206 and IIC-942A001 are anticipated to further fuel growth during the forecast period.
The African population is affected by this condition at a higher rate as compared to other regions due to lack of hygiene & sanitation, poor diet & nutritional status, and exposure to infectious diseases. However, there has been an increase in government initiatives for controlling elephantiasis cases which have led towards better treatment facilities for patients across various countries such as Kenya & Tanzania. This factor will also contribute towards regional market growth during the estimated time frame.
Growth Factors:
- Increasing prevalence of elephantiasis across the globe due to various reasons such as unhygienic living conditions, lack of awareness about the disease, and poor sanitation facilities.
- Growing demand for effective and affordable drugs for the treatment of elephantiasis.
- Rising number of research activities and initiatives undertaken by various organizations to find a cure for elephantiasis.
- Technological advancements in drug discovery and development processes that are expected to result in the introduction of novel drugs for treating elephantiasis in near future.
Scope Of The Report
Report Attributes
Report Details
Report Title
Elephantiasis Drug Market Research Report
By Type
EDE-1206, Flubendazole, IIC-942A001, S-0112091, Others
By Application
Clinic, Hospital, Others
By Companies
Johnson & Johnson, Anacor Pharmaceuticals, Inc., AbbVie Inc, Eisai Co Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
188
Number of Tables & Figures
132
Customization Available
Yes, the report can be customized as per your need.
Global Elephantiasis Drug Market Report Segments:
The global Elephantiasis Drug market is segmented on the basis of:
Types
EDE-1206, Flubendazole, IIC-942A001, S-0112091, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Johnson & Johnson
- Anacor Pharmaceuticals, Inc.
- AbbVie Inc
- Eisai Co Ltd
Highlights of The Elephantiasis Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- EDE-1206
- Flubendazole
- IIC-942A001
- S-0112091
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Elephantiasis Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Elephantiasis drug is a medication used to treat elephantiasis, a condition in which the skin becomes thick and hard. The medication can be applied topically or taken by mouth.
Some of the major players in the elephantiasis drug market are Johnson & Johnson, Anacor Pharmaceuticals, Inc., AbbVie Inc, Eisai Co Ltd.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Elephantiasis Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Elephantiasis Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Elephantiasis Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Elephantiasis Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Elephantiasis Drug Market Size & Forecast, 2018-2028
4.5.1 Elephantiasis Drug Market Size and Y-o-Y Growth
4.5.2 Elephantiasis Drug Market Absolute $ Opportunity
Chapter 5 Global Elephantiasis Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Elephantiasis Drug Market Size Forecast by Type
5.2.1 EDE-1206
5.2.2 Flubendazole
5.2.3 IIC-942A001
5.2.4 S-0112091
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Elephantiasis Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Elephantiasis Drug Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Hospital
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Elephantiasis Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Elephantiasis Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Elephantiasis Drug Analysis and Forecast
9.1 Introduction
9.2 North America Elephantiasis Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Elephantiasis Drug Market Size Forecast by Type
9.6.1 EDE-1206
9.6.2 Flubendazole
9.6.3 IIC-942A001
9.6.4 S-0112091
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Elephantiasis Drug Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Hospital
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Elephantiasis Drug Analysis and Forecast
10.1 Introduction
10.2 Europe Elephantiasis Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Elephantiasis Drug Market Size Forecast by Type
10.6.1 EDE-1206
10.6.2 Flubendazole
10.6.3 IIC-942A001
10.6.4 S-0112091
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Elephantiasis Drug Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Hospital
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Elephantiasis Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Elephantiasis Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Elephantiasis Drug Market Size Forecast by Type
11.6.1 EDE-1206
11.6.2 Flubendazole
11.6.3 IIC-942A001
11.6.4 S-0112091
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Elephantiasis Drug Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Hospital
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Elephantiasis Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America Elephantiasis Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Elephantiasis Drug Market Size Forecast by Type
12.6.1 EDE-1206
12.6.2 Flubendazole
12.6.3 IIC-942A001
12.6.4 S-0112091
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Elephantiasis Drug Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Hospital
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Elephantiasis Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Elephantiasis Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Elephantiasis Drug Market Size Forecast by Type
13.6.1 EDE-1206
13.6.2 Flubendazole
13.6.3 IIC-942A001
13.6.4 S-0112091
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Elephantiasis Drug Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Hospital
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Elephantiasis Drug Market: Competitive Dashboard
14.2 Global Elephantiasis Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Johnson & Johnson
14.3.2 Anacor Pharmaceuticals, Inc.
14.3.3 AbbVie Inc
14.3.4 Eisai Co Ltd
